Skip to main content
48°
Rain Shower
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
43.99
+0.29 (+0.66%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio
March 27, 2024
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
Via
InvestorPlace
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
March 27, 2024
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April....
Via
Benzinga
Exposures
Product Safety
Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer
March 21, 2024
The European Commission approved Bristol Myers Squibb's Abecma for relapsed/refractory multiple myeloma, making it the first CAR T cell therapy endorsed in the EU for earlier treatment lines.
Via
Benzinga
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...
Via
Benzinga
Check Out What Whales Are Doing With BMY
March 19, 2024
Via
Benzinga
Why NYSE:BMY is a Top Pick for Dividend Investors.
March 12, 2024
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing?
Via
Chartmill
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments
March 19, 2024
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer...
Via
Benzinga
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...
Via
Benzinga
Exposures
Product Safety
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
March 15, 2024
FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of...
Via
Benzinga
Exposures
Product Safety
What's Going On With Cancer Focused-Geron Stock On Friday?
March 15, 2024
Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date....
Via
Benzinga
Exposures
Product Safety
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
March 11, 2024
Via
Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
March 04, 2024
Via
Benzinga
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
February 22, 2024
Via
Benzinga
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...
Via
Benzinga
Exposures
Product Safety
Be A Smart Investor – Don’t Hold On For Dear Life
March 13, 2024
You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months.
Via
Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
February 21, 2024
Via
Benzinga
Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town
March 06, 2024
Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors.
Via
InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
March 04, 2024
Via
Benzinga
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
February 28, 2024
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D...
Via
Benzinga
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
The 3 Best Stocks Beginning Investors Can Buy: February 2024
February 21, 2024
Starting your investment journey? Navigate the market with confidence! Discover 3 stocks for beginning investors in this article.
Via
InvestorPlace
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside
February 21, 2024
Shares of these companies are trading at sizable earnings discounts.
Via
The Motley Fool
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
February 20, 2024
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
February 17, 2024
Patience will be rewarded with these stocks.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.